AxoGen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXGN research report →
Range $53 – $65
Price Chart
About the company
AxoGen, Inc. , along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions.
- CEO
- Michael D. Dale
- IPO
- 1986
- Employees
- 622
- HQ
- Alachua, FL, US
Get TickerSpark's AI analysis on AXGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.33B
- P/E
- -85.77
- Fwd P/E
- 100.64
- PEG
- 0.49
- P/S
- 12.48
- P/B
- 6.20
- EV/EBITDA
- -142.22
- Div Yield
- 0.00%
- Gross Margin
- 74.18%
- Op Margin
- -5.17%
- Net Margin
- -11.96%
- ROE
- -11.34%
- ROIC
- -2.68%
Latest fiscal year · YoY change
- Revenue
- $225.21M+20.2%
- Gross Profit
- $167.35M+17.9%
- Op Income
- $-7,849,000
- Net Income
- $-15,703,000-57.6%
- EPS
- $-0.34-47.8%
- OCF Growth
- -82.1%
- FCF Growth
- -26763.6%
- 52W High
- $59.72
- 52W Low
- $25.21
- 50D MA
- $44.07
- 200D MA
- $40.95
- Beta
- 1.15
- RSI (14)
- 69
- Avg Volume
- 1.59M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Axogen delivered 26.2% third-quarter revenue growth, expanded payer coverage, and raised full-year 2026 guidance while outlining BioCircuit and prostate as new growth drivers.· October 28, 2026
- Q3 revenue was $75.8 million, up 26.2% year over year, with growth across all markets and breast growth above 50% (management later said breast was over 60% in the quarter).
- Gross margin was 74.8%; adjusted EBITDA was $13.4 million and adjusted EBITDA margin improved by 2.3 percentage points year over year.
- Commercial payer coverage for Avance reached about 96% of covered lives after updates from Elevance and Aetna, which management said meets its near-universal coverage milestone.
- Axogen completed the BioCircuit acquisition on October 1 and expects NerveTape to add growth, with management saying the $34 million of next-year NerveTape sales discussed at closing is incremental net of cannibalization.
- The company plans to begin prostate nerve reconstruction market development in 2027, but prostate is not included in current or long-range guidance yet.
Axogen reported third-quarter 2026 revenue of $75.8 million, up 26.2% year over year. Gross profit was $56.7 million and gross margin was 74.8%, down from 76.6% a year ago but up from 72.7% in Q2. GAAP net income was $2.3 million, or $0.04 per share, versus $700,000, or $0.01 per share, in Q3 2025. Adjusted net income was $13.1 million, or $0.21 per share, versus $6.1 million, or $0.12 per share, and adjusted EBITDA was $13.4 million versus $9.2 million last year. For full-year 2026, management raised guidance to at least 29% revenue growth, or at least $290 million of revenue, including at least $7 million from BioCircuit; excluding BioCircuit, organic revenue is expected to be at least $283 million, or at least 26% growth. Gross margin is expected to be at least 73%, and free cash flow is expected to remain positive. Management also said gross margin should decline sequentially in Q4 and could be negatively affected by purchase-accounting inventory step-up from BioCircuit.
Michael Dale framed the quarter as strong across all six strategic priorities and said the company is “delighted” with both third-quarter and year-to-date results. He emphasized that growth is being driven by commercial footprint expansion, surgeon training, new account development, and broader adoption of nerve care as a standard of care. He also highlighted the strategic importance of NerveTape and prostate nerve reconstruction, saying both could expand the addressable market and support long-term growth.
Lindsey Hartley focused on the financial mechanics behind the quarter’s improvement: revenue of $75.8 million, gross profit of $56.7 million, gross margin of 74.8%, net income of $2.3 million, and adjusted EBITDA of $13.4 million. She said operating expenses were $55.8 million, up from $44.1 million a year ago, and noted $2 million of BioCircuit-related costs in the quarter. She also said cash, cash equivalents, restricted cash and investments totaled $350.1 million at September 30, 2026, and that free cash flow was $18.9 million through the first nine months of 2026. On capital allocation and outlook, she said the BioCircuit purchase price of $200 million plus transaction expenses was funded, the guidance assumes some integration/disruption risk, and the company expects full-year 2026 positive free cash flow.
Analysts focused heavily on breast growth, NerveTape cannibalization, Aetna coverage, and prostate market timing. Management said breast penetration is probably around 11%, growth is coming from same-store productivity, new surgeons, and new accounts, and they expect the category to keep growing for years. On NerveTape, management said the $34 million sales figure discussed at closing is incremental and net of cannibalization, but also acknowledged that some mix shift from Connector is expected; they said the broader thesis remains highly synergistic. On Aetna, management said Aetna and CVS Health generally comply with WHCRA and that they are confident they can resolve the policy issue collaboratively. On prostate, management said the initial target is academic and high-volume centers, and that they do not expect clinical guideline changes in the next 12 months.
The bull case from this call is that Axogen is still seeing strong underlying demand, with double-digit growth across markets, improving profitability, and broader payer coverage. The company also has multiple longer-term growth options in front of it: BioCircuit/NerveTape, prostate nerve reconstruction, and continued expansion in breast and extremities.
The main risks flagged on the call are gross margin pressure from longer-length Avance demand, acquisition-related integration and inventory step-up effects, and uncertainty around NerveTape cannibalization versus true incremental growth. Management also acknowledged that Aetna’s new coverage criteria need to be worked through, and that prostate is still a future initiative not yet included in guidance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.4%
- Shares Outstanding
- 59.73M
- Float Shares
- 54.61M
of shares held by institutions
260 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AXGN, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.58M | ▲ 161.24K |
| Vanguard Group Inc | 2.87M | ▲ 190.56K |
| First Light Asset Management, LLC | 2.75M | ▼ 1.25M |
| Fmr LLC | 2.64M | ▲ 1.42M |
| Vanguard Capital Management LLC | 2.43M | ▲ 175.62K |
| Morgan Stanley | 1.79M | ▼ 957.82K |
| Artemis Investment Management Llp | 1.78M | ▲ 384.20K |
| Geode Capital Management, LLC | 1.65M | ▲ 274.38K |
| Polar Capital Holdings PLC | 1.50M | 0 |
| Wellington Management Group Llp | 1.39M | ▲ 427.09K |
| Citadel Advisors LLC | 1.36M | ▲ 1.12M |
| State Street Corp | 1.28M | ▲ 33.42K |
Held by 277 ETFs
Biggest fund positions in AXGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 2, 26 | TYNDALL JOSEPH A. | sell | 3,500 |
| Aug 10, 26 | Began Marc A | other | 67,500 |
| Aug 10, 26 | Began Marc A | sell | 67,500 |
| Aug 10, 26 | Began Marc A | other | 67,500 |
| Aug 11, 26 | Wendell Amy McBride | other | 13,353 |
| Aug 11, 26 | Wendell Amy McBride | sell | 13,353 |
| Aug 11, 26 | Wendell Amy McBride | other | 13,353 |
| Aug 7, 26 | Weiler Kathy Johnson | sell | 14,150 |
| Jun 24, 26 | Burke William P. Mr. | other | 4,392 |
| Jun 24, 26 | JOHNSON JOHN | other | 4,392 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AXGN coverage
Recent articles, reports, and earnings notes.
No research on AXGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AXGN report →AxoGen: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
zacks.com · Nov 12
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
seekingalpha.com · Nov 9
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
globenewswire.com · Nov 3
GMED vs. AXGN: Which Stock Should Value Investors Buy Now?
zacks.com · Nov 2
Axogen: Taking The Friction Out Of Nerve Repair
seekingalpha.com · Oct 30
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
zacks.com · Oct 29
AxoGen Q3 Earnings Call Highlights
marketbeat.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.